A recent review revisited the question of whether inhalers and nebulizers have similar effectiveness to manage stable chronic obstructive pulmonary disease (COPD). A recent review revisited the ...

For individuals living with COPD, small changes may make a difference. Viatris Inc. and Theravance Biopharma US, Inc. COPD, or chronic obstructive pulmonary disease, is a group of life-changing lung ...

Breathing devices, including inhalers, nebulizers, and larger devices, can help improve your breathing with COPD. Which device a doctor recommends can depend on your symptoms. If you’re living with ...

COPD stands for chronic obstructive pulmonary disease. The condition causes lung inflammation that leads to airflow blockage and breathing problems. [1] “COPD encompasses both emphysema and chronic ...

After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer therapy ...

Sunovion’s COPD treatment passed muster in Phase III for both safety and efficacy, marking a success for its quick-acting nebulizer delivery system. The SUN-101/eFlow system, described as a ...

The first DTC ad campaign for Viatris and Theravance’s COPD nebulizer therapy Yupelri aims to show the freedom of the once-daily treatment. In a newly debuted TV ad, an older woman celebrates her ...

Medicare classifies nebulizers as durable medical equipment (DME), which is covered under Part B. Part A may cover costs if needed during inpatient care in a clinic, hospital, or nursing facility.

The United States nebulizer market is set to grow from US$ 466.55 million in 2024 to US$ 730.62 million by 2033, with a CAGR of 5.11%. This growth is driven by the rising prevalence of respiratory ...